Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00579085 · ClinicalTrials.gov registry record · Phase 2
Double Blind Placebo Controlled Study of Outpatient Intravenous Ketamine for the Treatment of CRPS
A Phase 2 study, sponsored by Drexel University College of Medicine.
- Completed
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
NCT00579085 is a Phase 2 study that has completed, run by Drexel University College of Medicine. The registered enrollment target is 40 participants.
The verdict
NCT00579085, a Phase 2 study, has completed, sponsored by Drexel University College of Medicine.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
Study Summary
Complex Regional Pain Syndrome is a debilitating and extremely difficult to treat condition. There is a large body of evidence demonstrating the therapeutic value of N-methyl-D-aspartate (NMDA)-receptor antagonists in CRPS. The NMDA antagonist ketamine has been shown to be effective in the treatment of CRPS, resulting in complete remission of the disease in some patients. The purpose of this study is to evaluate intravenous outpatient infusion of sub-anesthetic doses of ketamine for the treatment of CRPS. A thorough evaluation of this procedure, providing information into the degree of relief and which of the constellation of RSD symptoms are best alleviated by this procedure would result in the optimization of this therapy for the treatment of CRPS.
Interventions
- DRUG Ketamine
- OTHER Normal Saline
- OTHER IV NSS
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2006-09 |
| Est. Completion | 2009-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00579085
The ClinicalTrials.gov registry entry for NCT00579085 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Drexel University College of Medicine, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Ketamine is the first listed.
NCT00579085 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00579085 about?
NCT00579085 is a clinical study titled "Double Blind Placebo Controlled Study of Outpatient Intravenous Ketamine for the Treatment of CRPS". Complex Regional Pain Syndrome is a debilitating and extremely difficult to treat condition. There is a large body of evidence demonstrating the therapeutic value of N-methyl-D-aspartate (NMDA)-receptor antagonists in CRPS. The NMDA antagonist ketamine has been shown to be effective in the treatment...
What is the current status of trial NCT00579085?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2006-09. Estimated completion is 2009-11.
What interventions are being tested in trial NCT00579085?
The interventions under investigation include: Ketamine (DRUG), Normal Saline (OTHER), IV NSS (OTHER).
Who is sponsoring clinical trial NCT00579085?
This trial is sponsored by Drexel University College of Medicine, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.